Group 1: Market Overview - A total of 65 stocks hit the daily limit up in the A-share market, with 50 stocks remaining after excluding 15 ST stocks, resulting in a limit-up rate of 68.42% [1] Group 2: Notable Stocks - Yiming Pharmaceutical saw a limit-up with a closing order amount exceeding 4 billion yuan, following a significant share transfer agreement that changed its controlling shareholder [2] - The highest closing order volume was recorded by Zhongjia Bochuang with 378,900 hands, followed by Haitai Development and Yiming Pharmaceutical [2] - ST United achieved a six-day consecutive limit-up, while several other stocks also recorded multiple consecutive limit-ups [2][3] Group 3: Mergers and Acquisitions - ST United plans to acquire 100% of Run Tian Industrial and raise matching funds [3] - Haitai Development is planning to acquire controlling stakes in Zhixueyun (Beijing) Technology Co., Ltd. [4] - Hunan Development intends to purchase stakes in multiple hydropower companies, including 85% of Hunan Xiangtou Yuanling Power Co., Ltd. [4] Group 4: Silver Industry - Hunan Silver focuses on silver-related operations including mining, smelting, materials, and trading [5] - Baiyin Youse reported a silver metal reserve of 1,832.5 tons as of the end of December 2024 [6] - Shengda Resources has a total verified silver metal amount of approximately 12,000 tons across its seven mining subsidiaries [6] Group 5: Computing Power Sector - Huamai Technology is expanding its communication infrastructure and developing data centers and IoT services [7][8] - Erli San has comprehensive capabilities in computing, storage, and network infrastructure, supporting data centers and mobile communications [8] - Nanling Technology provides cloud connectivity between local data centers and cloud platforms, catering to the demand for hybrid cloud computing environments [8] Group 6: Institutional Investments - Changshan Pharmaceutical received a net purchase of over 200 million yuan from the Shenzhen Stock Connect [9] - The top net purchases by institutional seats included Xue Ren Co., Ltd. and Changshan Pharmaceutical [9]

Core Viewpoint - Shenzhen New Star reported a significant increase in total revenue for 2024, but continued to face substantial net losses, marking the third consecutive year of losses for the company [1][3]. Financial Performance - Total revenue for 2024 reached 2.565 billion yuan, representing a year-on-year increase of 62.40% compared to 1.579 billion yuan in the previous year [2]. - The net profit attributable to shareholders was -291 million yuan, a decline of 105.99% from -141 million yuan in the previous year [2]. - The net profit excluding non-recurring items was -293 million yuan, down 105.25% from -143 million yuan year-on-year [2]. - Basic earnings per share were -1.70 yuan, a decrease of 57.41% from -1.08 yuan in the previous year [2]. - The weighted average return on net assets was -19.16%, a decrease of 10.65 percentage points from -8.51% in the previous year [2]. Historical Performance - The company has reported net losses for three consecutive years, with net profits of -48 million yuan in 2022 and -1.41 billion yuan in 2023 [3]. - The net profit excluding non-recurring items was -57 million yuan in 2022 and -1.43 billion yuan in 2023 [3]. Future Outlook - For the first quarter of 2025, the company anticipates a net profit attributable to shareholders of between 2 million and 3 million yuan, which would represent an increase of 42.16 million to 43.16 million yuan compared to the same period last year [4]. - The expected net profit excluding non-recurring items for the first quarter of 2025 is projected to be between -52,000 and -35,000 yuan, indicating a reduction in losses by 41.40 million to 41.57 million yuan compared to the previous year [4].